Arbejdsmarkedets Tillaegspension Buys Shares of 233,477 Medtronic PLC $MDT

Arbejdsmarkedets Tillaegspension acquired a new stake in shares of Medtronic PLC (NYSE:MDT) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 233,477 shares of the medical technology company’s stock, valued at approximately $22,428,000.

A number of other large investors have also made changes to their positions in MDT. Brighton Jones LLC boosted its stake in shares of Medtronic by 1,368.0% during the fourth quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after acquiring an additional 37,265 shares during the last quarter. Sivia Capital Partners LLC boosted its stake in Medtronic by 9.6% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock worth $380,000 after buying an additional 381 shares during the last quarter. Jump Financial LLC acquired a new stake in Medtronic in the 2nd quarter worth about $299,000. Main Street Financial Solutions LLC boosted its stake in Medtronic by 28.9% in the 2nd quarter. Main Street Financial Solutions LLC now owns 14,356 shares of the medical technology company’s stock worth $1,251,000 after buying an additional 3,218 shares during the last quarter. Finally, HUB Investment Partners LLC boosted its stake in Medtronic by 21.3% in the 2nd quarter. HUB Investment Partners LLC now owns 19,226 shares of the medical technology company’s stock worth $1,676,000 after buying an additional 3,376 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Price Performance

Shares of MDT opened at $76.12 on Friday. Medtronic PLC has a 52 week low of $74.40 and a 52 week high of $106.33. The firm has a market cap of $97.73 billion, a price-to-earnings ratio of 21.20, a PEG ratio of 1.83 and a beta of 0.62. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57. The stock has a 50 day moving average of $84.76 and a 200-day moving average of $93.64.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The firm had revenue of $9.02 billion for the quarter, compared to the consensus estimate of $8.89 billion. During the same quarter in the previous year, the business earned $1.38 EPS. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, analysts forecast that Medtronic PLC will post 5.57 EPS for the current year.

Medtronic Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, April 17th. Investors of record on Friday, March 27th were given a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a dividend yield of 3.7%. The ex-dividend date of this dividend was Friday, March 27th. Medtronic’s payout ratio is currently 79.11%.

Analysts Set New Price Targets

MDT has been the topic of a number of research analyst reports. Jefferies Financial Group reissued a “hold” rating and issued a $95.00 price target on shares of Medtronic in a research note on Thursday, April 23rd. Stifel Nicolaus decreased their price target on Medtronic from $105.00 to $95.00 and set a “hold” rating on the stock in a research note on Monday, April 6th. UBS Group decreased their price target on Medtronic from $104.00 to $90.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 22nd. Barclays raised their price target on Medtronic from $118.00 to $120.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 1st. Finally, Weiss Ratings downgraded Medtronic from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, April 21st. Fifteen research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the stock. According to MarketBeat.com, Medtronic presently has a consensus rating of “Moderate Buy” and a consensus target price of $107.80.

Insider Buying and Selling at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the transaction, the executive vice president owned 32,768 shares of the company’s stock, valued at $3,201,761.28. This represents a 61.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 0.26% of the company’s stock.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).